beyond pink team
  • Home
  • About Us
    • Who We Are
    • Our Board
    • Annual Report
    • Contact Us
  • Support
    • Physical
    • Emotional
    • Community
    • Financial
    • Caregiver
    • Online
  • Education
    • Newsletter
    • Ignite the Cancer Conversation
    • Quality Care
    • Resources
    • Request Speaker
    • The Cancer Journey
  • Advocacy
    • What is Advocacy
    • National Breast Cancer Coalition
    • Iowa Stop Breast Cancer
    • Research
    • Influencing Policy
    • Access to Care
  • Join Us
    • Be an Advocate
    • Volunteer
    • Events >
      • 16th Annual Pink Ribbon Run
    • Membership
    • Donate to BPT
    • Follow Us
 If you are Breast Cancer Survivor and  you would like to contribute your story to our Newsletter, 
​please send us a message here.
DOWNLOAD Current NewsletteR

Categories

All
Advocacy
Bone Health
Breast Density
Breast Disease
Caregivers
COVID 19
COVID-19
Emotional Support
Environment
Exercise
Fatigue
Financial
Gender
Genetic Testing
Grief
High Risk
Hormone Replacement Therapy
Ignite
Implants
Intimacy After Cancer
LGBTQ
Lymphedema
Mammography
Meditation
Men
Mental Health
Metastasis
MRI
NBCC
Nutrition
Obesity
Pain
Pregnancy
Prevention
Radiation
Reconstruction
Reduce Risk
Rehabilitation
Screening
Sex
Side Effects
Support Groups
Surgery
Survivor
Survivorship
Treatment
Vaccine
Yoga
Young Women

Archives

January 2023
October 2022
July 2022
April 2022
January 2022
October 2021
July 2021
April 2021
January 2021
October 2020
July 2020
April 2020
January 2020
October 2019
July 2019
April 2019
January 2019
October 2018
July 2018
April 2018
January 2018
October 2017
July 2017
April 2017
January 2017
October 2016
July 2016
April 2016
January 2016
October 2015
July 2015
April 2015
January 2015
October 2014
July 2014
April 2014
January 2014
October 2013
July 2013
April 2013
January 2013
October 2012
July 2012
April 2012
January 2012
October 2011
July 2011
April 2011
January 2011
October 2010
July 2010
April 2010
January 2010
October 2009
July 2009
April 2009
January 2009
October 2008
July 2008
April 2008
January 2008
October 2007
July 2007
April 2007
January 2007
October 2006
July 2006
April 2006
January 2006
October 2005
July 2005
April 2005
January 2005
October 2004
July 2004
April 2004
January 2004

What is metastasis?

10/1/2021

0 Comments

 
by Barbara Christie-Pope, PhD
Professor of Biology, Cornell College


Metastasis is the movement of cancer cells from a primary tumor to a distant site in the body. This simple definition does not capture the fear and devastation felt by an individual when they learn that they have metastatic disease. The initial reaction is, why did this happen? Why didn’t my therapy work? I thought I was “cancer-free”; how could this come back to haunt me ten years later? Is there something I did that caused this? The questions are endless and sometimes overwhelming.

Unfortunately, these questions lack answers. Around 90% of all cancer mortality is due to metastasis; therefore, research is necessary to treat metastatic disease and to prevent metastasis in the first place. The mechanisms underlying the development of metastatic tumors, often referred to as the metastatic cascade, is poorly understood but many avenues of research are piecing together the route tumor cells must travel to new sites in the body and, once there, how these cells respond to their new, foreign environment.

The cascade begins when a cell from the primary tumor detaches and enters the lymph circulation and on to the blood or enters the blood directly. This process requires the cells to navigate through the blood vessel wall, travel through the blood, then exit the blood vessel to gain entry to tissues. Tumor cells in the blood are met with a very hostile physical and cellular environment. These cells enter a fast-flowing river where they encounter obstacles such as the inner banks of the blood vessel wall. The shearing forces and pressure within the blood vessel can damage their fragile cell walls. Cells of the immune system are also found in blood. These natural killer cells are appropriately named and have the ability to recognize the tumor cells and destroy them. Unfortunately, platelets, small fragments of cells involved in blood clotting, can form a protective barrier around the tumor cells allowing survival and assisting with the exit of the tumor cells into the tissue surrounding the blood vessel.

Although thousands of cells may begin this arduous journey, few actually survive. This sounds like good news. But unfortunately, it only takes one seeding cell to begin the new formation of a secondary tumor.

In addition, these disseminated tumor cells, or DTCs, usually begin this cascade prior to detection of the primary tumor. Once leaving the blood and entering another tissue or organ, DTCs encounter a new environment, the so-called microenvironment, which contributes to and may determine their survival, their ability to stop multiplying and remain quiescent or dormant, and their resistance to therapy.

But, if cancer therapy is systemic or administered all over the body, how do DTCs escape this therapy only to revive and begin multiplying into a secondary tumor years to decades later? Because most cancer therapies target rapidly dividing cells, non-dividing DTCs are resistant to these therapies. We need strategies to target DTCs by either keeping them dormant and stopping their reactivation or destroying them. Current research is identifying the factors including proteins and genes that determine and regulate the interactions between DTCs and the environment surrounding them. Therapies that target these interactions could conceivably halt the recurrence of cancer. Unfortunately, there are no tests to determine where DTCs are in the body; therefore, it is challenging to determine whether or not an individual will experience metastatic disease.

DTCs are ticking time-bombs. Defusing these bombs is going to take more research and is a major therapeutic challenge. Want to find out more about how researchers are working to prevent or stop metastasis and death from cancer? On Tuesday, October 19, 2021, from 5:30-8:30 via zoom, Beyond Pink TEAM will feature Dr. Cyrus Ghajar, whose groundbreaking research into dormant cancer cells and the environments within which they may awaken is one of the most promising new developments in cancer research. Dr. Ghajar studies how the microenvironments within distant tissues regulate DTC dormancy and/or growth. He believes that solving these puzzles will allow the development of drugs that eradicate dormant DTCs before they can develop into full-blown metastases. He conducts this work within the Fred Hutchinson Cancer Center Laboratory for the Study of Metastatic Microenvironments.
​Register for the Ignite the Cancer Conversation event here.


​
Read Full Newsletter Here
0 Comments



Leave a Reply.

CONTACT US

Beyond Pink TEAM
c/o Jeanne Olson, Treasurer
1407 Asbury Lane
Waterloo, IA 50701
​beyondpinkteam@gmail.com
(319) 239-3706
©2020 Beyond Pink TEAM
  • Home
  • About Us
    • Who We Are
    • Our Board
    • Annual Report
    • Contact Us
  • Support
    • Physical
    • Emotional
    • Community
    • Financial
    • Caregiver
    • Online
  • Education
    • Newsletter
    • Ignite the Cancer Conversation
    • Quality Care
    • Resources
    • Request Speaker
    • The Cancer Journey
  • Advocacy
    • What is Advocacy
    • National Breast Cancer Coalition
    • Iowa Stop Breast Cancer
    • Research
    • Influencing Policy
    • Access to Care
  • Join Us
    • Be an Advocate
    • Volunteer
    • Events >
      • 16th Annual Pink Ribbon Run
    • Membership
    • Donate to BPT
    • Follow Us